Edit

HBM Healthcare Investments

https://hbmhealthcare.com
Last activity: 25.06.2025
Active
News
321
Portfolio
4
Mentions
71
Employees: 11-50
Investment Stage: Series B; IPO

Portfolio 4

DateNameWebsiteTotal RaisedLocation
28.03.2023ArriVent B...arrivent.com$415MUnited Sta...
17.10.2022Odyssey Th...odysseytx.com$487MUnited Sta...
18.06.2019Viela Bio ...vielabio.com$600MUnited Sta...
28.04.2017Amicusamicuspharma.eu$21.79MSwitzerlan...

News 321

DateTitleDescription
02.04.2024Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 248.10 as at 31 March 2024 and quarterly profit of CHF 156 millionHBM Healthcare Investments generated a profit of CHF 156 million in the final quarter of the 2023/24 financial year as at the end of March. This largely made up for the loss from the first nine months. The net asset value per share (NAV) ro...
22.01.2024Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2023 with key figures for the first nine months of the 2023/2024 financial yearUnfavourable currency developments drag HBM Healthcare into the red
03.01.2024Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 225.03 as at 31 December 2023HBM Healthcare Investments closed the 2023 calendar year with a negative performance due to unfavourable currency developments. The net asset value per share (NAV) fell by 8.3 percent to CHF 225.03. The share price declined by 5.4 percent t...
30.11.2023AbbVie to acquire HBM portfolio company ImmunoGen for USD 10.1 billion in cashHBM Healthcare Investments today announced that its portfolio company ImmunoGen (NASDAQ: IMGN) will be acquired by AbbVie (NYSE: ABBV) for USD 10.1 billion in cash. The acquisition price of USD 31.26 per ImmunoGen share represents a premium...
16.10.2023Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments activates share buyback programmeThe discount of the share price to the reported net asset value per share (NAV) has widened in recent days to an extent that the Board of Directors and the Management of HBM Healthcare Investments are convinced does not reflect the fundamen...
16.10.2023Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2023 with key figures for the second quarter of the 2023/2024 financial year
02.10.2023Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 237.22 as at 30 September 2023The net asset value per share (NAV) fell by 4.0 per cent to CHF 237.22 in the first six months of the 2023/2024 financial year. The performance thus is in line with the performance of the biotechnology sector as measured by the Nasdaq Biote...
21.07.2023Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes interim report for the quarter ended 30 June 2023 with key figures for the first three months of the 2023/2024 financial ...Unfavourable currency developments push quarterly result into the red
26.06.2023Ad hoc announcement pursuant to Art. 53 LRCathay Biotech raises capital and enters into major strategic collaboration with China Merchants GroupCathay Biotech, the largest holding in HBM Healthcare Investments' portfolio (15% of net assets), yesterday announced a significant strategic collaboration with China Merchants Group (CMG). The transaction, which is subject to approval by C...
26.05.2023Ad hoc announcement pursuant to Art. 53 LRPublication of Annual Report 2022/2023 and Invitation to the Ordinary Shareholders’ MeetingThe invitation to the 22nd Ordinary Shareholders’ Meeting on 19 June 2023 has been sent to the shareholders of HBM Healthcare Investments today.
Show more

Mentions in press and media 71

DateTitleDescription
25.06.2025Neuron23: Pioneering Precision Medicine with a $96.5 Million BoostIn the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici...
25.06.2025Neuron23 Raises $96.5M in Series D FinancingNeuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding. The round wa sled by heal...
24.06.2025Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological MedicinesNeuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar...
28.05.2025FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 FinancingIn the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m...
23.05.2025FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of PlixorafenibFORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare...
18.03.2025Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in ImmunizationIn the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa...
18.03.2025Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein ShinglesCurevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm...
17.03.2025Curevo Raises $110M in Series B FundingCurevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding. The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca...
10.01.2025Numab Therapeutics: A Financial Surge in the Fight Against CancerIn the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c...
09.01.2025Numab raises additional CHF50 million In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In